New insider activity at Guardant Health ( (GH) ) has taken place on September 15, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Hidalgo Medina Manuel has recently sold 2,165 shares of Guardant Health stock, amounting to a total value of $117,234.
Recent Updates on GH stock
Guardant Health has experienced notable developments in the past 24 hours, including a strategic agreement with LabFlorida to distribute its FDA-approved colorectal cancer screening test, Guardant Shield, to senior living communities in Florida. Additionally, the company expanded its Board of Directors by appointing Alex M. Azar II, which is expected to enhance its precision oncology initiatives. Despite these positive strides, Guardant’s stock fell by 7% following the release of its Shield V2 algorithm data. The data showed an 84% sensitivity for colorectal cancer detection, which was slightly below bullish expectations. However, BTIG raised its price target for Guardant, citing improvements in the Shield test’s sensitivity and the company’s leadership in liquid biopsy technology. Analysts remain optimistic about Guardant’s market position, though concerns about financial performance and valuation persist due to ongoing losses.
Spark’s Take on GH Stock
According to Spark, TipRanks’ AI Analyst, GH is a Neutral.
Guardant Health’s overall stock score is driven by strong technical indicators and a positive earnings call, which highlight significant revenue growth and improved margins. However, financial performance and valuation concerns due to ongoing losses and negative equity weigh down the score.
To see Spark’s full report on GH stock, click here.
More about Guardant Health
YTD Price Performance: 72.79%
Average Trading Volume: 2,487,955
Technical Sentiment Signal: Buy
Current Market Cap: $6.85B